EICHOR
● Completed
Roflumilast or Azithromycin to Prevent COPD Exacerbations Trial
Condition: Chronic Obstructive Pulmonary Disease Severe · Chronic Bronchitis · Sponsor: Johns Hopkins University
About this study
A multi-center, randomized, 72-month, parallel- group, non-inferiority, phase III study to compare the effectiveness of roflumilast (Daliresp, 500 mcg quaque die (QD) or alternate regimen) therapy versus azithromycin (250 mg QD, 500 mg QD three times per week, or alternate regimen) to prevent hospitalization or death in a patients at high risk for COPD exacerbations.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (28)
| University of Alabama | Birmingham, Alabama, United States | — |
| University of Arizona | Tucson, Arizona, United States | — |
| University of California, Davis Health | Sacramento, California, United States | — |
| Northwestern | Chicago, Illinois, United States | — |
| University of Illinois Chicago | Chicago, Illinois, United States | — |
| NorthShore Hospital | Glenview, Illinois, United States | — |
| University of Iowa | Iowa City, Iowa, United States | — |
| University of Kansas | Kansas City, Kansas, United States | — |
| Ochsner Medical Center | New Orleans, Louisiana, United States | — |
| Johns Hopkins University | Baltimore, Maryland, United States | — |
| Baystate Health | Springfield, Massachusetts, United States | — |
| University of Michigan | Ann Arbor, Michigan, United States | — |
+ 16 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04069312